Privi Speciality Chemicals Limited announced the outcome of its Board meeting held on February 09, 2026. The board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. Crucially, the board also approved an equity investment of ₹50 Crores in its subsidiary, Prigiv Specialties Private Limited, to support its growth plans.
Financial Performance for Nine Months Ended December 31, 2025
The Board of Directors of Privi Speciality Chemicals Limited met on Monday, February 09, 2026, to review and approve key matters. The primary outcome was the adoption of the unaudited financial results for the third quarter and the cumulative nine months period ending December 31, 2025.
Consolidated Financial Highlights (Nine Months Ended Dec 31, 2025)
The consolidated results show significant operational scale:
- Total Income: Reached ₹1,85,722.59 Lakhs.
- Profit Before Tax (PBT): Stood at ₹31,002.03 Lakhs.
- Net Profit Attributable to Owners of the Holding Company: Totaled ₹23,383.76 Lakhs.
- Earnings Per Share (EPS): Basic and Diluted EPS was reported at ₹59.86 (not annualised) for the nine-month period.
Standalone Financial Performance (Nine Months Ended Dec 31, 2025)
Key standalone figures:
- Total Income: Amounted to ₹1,45,761.41 Lakhs.
- Profit Before Tax (PBT): Stood at ₹18,559.15 Lakhs.
- Net Profit Attributable to Owners of the Holding Company: Totaled ₹12,073.38 Lakhs.
- EPS (Basic & Diluted): Calculated at ₹31.53 (not annualised).
Strategic Equity Infusion in Subsidiary
The Board also approved a significant investment in its subsidiary, Prigiv Specialties Private Limited.
The total approved equity investment is set at ₹50 Crores. This infusion will be executed in the existing shareholding ratio of 51:49. Privi Speciality Chemicals Limited will contribute 51% of this capital, amounting to ₹25.5 Crores. The remaining 49% will be contributed by the Joint Venture Partner, Givaudan SA.
This capital infusion is strategically aimed at supporting the subsidiary’s growth plans, which is expected to lead to higher revenue and improved profitability moving forward. Prigiv Specialties Private Limited, incorporated on September 1, 2021, primarily focuses on the manufacturing of Chemicals, aligning with Privi’s main business.
Related Party Transaction Details
The investment in Prigiv Specialties Private Limited is classified as a related party transaction. The investment decision, including the acquisition of equity shares at par value (face value of ₹10/- each), is confirmed to be conducted on an ‘arm’s length basis‘. Key promoters, Mr. Mahesh P Babani and Ms. Jyoti Mahesh Babani, represent the Company on Prigiv’s Board.
Auditor Confirmation and Labour Code Impact
The financial results were subjected to a Limited Review by the statutory auditors, BSR & Co. LLP, who expressed an unmodified conclusion. Furthermore, management disclosed the impact of the new consolidated labour codes enacted on November 21, 2025, resulting in an incremental provision of ₹389.96 Lakhs towards employee benefit expenses in the consolidated results.
Source: BSE
